Skip to main content
. 2013 Feb 3;138(1):149–155. doi: 10.1007/s10549-012-2395-8

Table 4.

Analysis of duration of clinical benefit

Fulvestrant 500 mg (n = 362) Fulvestrant 250 mg (n = 374)
Response rate (%) 45.6 39.6
Mean DoCBa in months (SE) 21.6 (1.3) 18.3 (1.1)
Expected DoCB (months) 9.8 7.2
Ratio of expected DoCB (95 % CI)b 1.36 (1.07–1.73)
P value 0.013

CI confidence interval, DoCB duration of clinical benefit, SE standard error

aLimited to patients with clinical benefit, i.e. a subset of all randomized patients

bRatios of >1 favor fulvestrant 500 mg